AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY25 earnings guidance on Thursday. The company provided earnings per share guidance of ($0.42)-($0.38) for the period, compared to the consensus earnings per share estimate of ($0.41). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $284.37 million. AngioDynamics also updated its FY 2025 guidance to -0.420–0.380 EPS.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ANGO. HC Wainwright reissued a buy rating and issued a $14.00 price target on shares of AngioDynamics in a research report on Friday, September 20th. Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $18.00 to $13.00 and set a buy rating for the company in a report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $12.25.
Read Our Latest Research Report on ANGO
AngioDynamics Price Performance
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $71.00 million during the quarter, compared to analyst estimates of $70.86 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. AngioDynamics’s revenue for the quarter was down 22.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 earnings per share. On average, sell-side analysts expect that AngioDynamics will post -0.41 EPS for the current year.
AngioDynamics Company Profile
AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
Read More
- Five stocks we like better than AngioDynamics
- Stock Dividend Cuts Happen Are You Ready?
- SCHD ETF: Unlocking Passive Income With Strong Returns
- The Role Economic Reports Play in a Successful Investment Strategy
- NuScale Power Soars 270% – Analysts Forecasts More Gains Ahead
- Which Wall Street Analysts are the Most Accurate?
- Harness the Power of Dividend ETFs for Steady Income Growth
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.